Company Focus
Bristol Myers Squibb
Latest Bristol Myers Squibb News
Biotechnology
Switzerland-based Philochem and Bristol Myers Squibb radiopharma subsidiary RayzeBio have announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. 11 June 2025
Related News
Insights
Company Spotlight
A biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes.
Latest News & Features of interest to Bristol Myers Squibb
Biotechnology
Israel’s Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. 17 June 2025
Biotechnology
Scientists at The Institute of Cancer Research, London, claim to have discovered what may cause some treatments to stop working in people living with bowel cancer. 16 June 2025
Pharmaceutical
Supernus Pharmaceuticals is to buy Sage Therapeutics for total consideration of around $795 million. 16 June 2025
Biotechnology
A second case of acute liver failure (ALF) resulting in the death has been reported in a young recipient of Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy. 16 June 2025
Biotechnology
Swiss pharma giant Roche announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease (PD). 16 June 2025
Biotechnology
Boston, USA-based biotech Solu Therapeutics today announced the appointment of Enda Moran as chief operating officer (COO). 16 June 2025
Biotechnology
French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST Phase IV study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. 16 June 2025
Biotechnology
US healthcare giant Johnson & Johnson’s subsidiary Janssen-Cilag yesterday announced today new results from the Phase II RedirecTT-1 study evaluating the investigational combination of Talvey talquetamab) and Tecvayli teclistamab). 16 June 2025
Biotechnology
Californian biotech Jasper Therapeutics presented data from the 180mg cohort of the company’s SPOTLIGHT Phase Ib/IIa study of subcutaneous briquilimab in adult participants with chronic inducible urticaria (CIndU) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. 16 June 2025
Biotechnology
Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) demonstrated clinically-meaningful overall survival at 26 weeks in pediatric patients (aged 28 days to <18 years of age) with thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT). 16 June 2025
Latest In Brief for Bristol Myers Squibb
Biotechnology
The US Food and Drug Administration (FDA) announced a forthcoming public advisory committee meeting (AdCom) of the Oncologic Drugs Advisory Committee to review GSK’s marketing application for Blenrep (belantamab mafodotin. 16 June 2025
Latest Relevant Ones To Watch News
US pharma major Eli Lilly (today announced a definitive agreement to acquire Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, sending Verve’s shares up 77.7% to $11.15 in premarket trading. 17 June 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze